Cancer Vaccines Market is Forecast to Show High Growth until 2018

Monday 17 October 2011, Amsterdam

This new study estimates that the global cancer vaccines market was worth $3,483.0m in 2010, after increasing at a compound annual growth rate (CAGR) of 63.7% during 2006–2010. During 2010–2018, the market is expected to record a CAGR of 12.7%, to reach $9,077.9m by 2018. This high growth is attributed to the increasing patient population of cancer. Cancer is the most common cause of death globally. The high growth rate is due to expected introduction of promising vaccines during the forecast period. The cancer vaccines market is divided into the prophylactic cancer vaccines market and the therapeutic cancer vaccines market.

The prophylactic cancer vaccines market experienced high growth in the historic period due to the launch of Gardasil (human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant) and Cervarix (human papillomavirus bivalent (types 16 and 18) vaccine, recombinant). Gardasil was approved in the US and Europe in 2006 and in Japan in 2011. Similarly, Cervarix was launched in Europe in 2008 and in the US and Japan in 2009. The Prophylactic cancer vaccines market is expected to grow in the forecast period to 2018 due to the label extension of Gardasil. In December 2010, the FDA approved a new indication for Gardasil, anal cancer and anal intraepithelial neoplasia grades 1, 2 and 3 in males and females between the age of 9 and 26, which is expected to drive the prophylactic cancer vaccine market. The expected launch of the first-in-class vaccine, V503 in 2014, is also expected to drive the prophylactic cancer vaccine market during the forecast period. V503 is a multivalent vaccine and is believed to provide greater protection from many strains of HPV (human papillomavirus) than the existing vaccines in the market, which are either tetravalent or bivalent, thereby lowering the risk of cervical cancer. The prophylactic cancer vaccine market will grow during the forecast period but will not show significant growth because V503 will uptake the market of Gardasil and there will be little change in the market.

The cancer vaccines therapeutic market is expected to show high growth in the forecast period to 2018 due to the expected launch of first-in-class therapeutic cancer vaccines. Presently, there is only one therapeutic cancer vaccine, Provenge, which is a dendritic cell vaccine for advanced prostate cancer patients. Provenge received approval in April 2010 and is presently available only in the US. Dendreon is expecting to file Provenge in Europe in early 2012 and is expected to be launched on the market by mid-2013, which will help drive the therapeutic cancer vaccine market during the forecast period. The expected launch of first-in-class vaccines for different types of cancer during the forecast period to 2018 is expected to drive the cancer vaccines therapeutics market. These drugs include:

• Allovectin-7 for Melanoma
• BiovaxId (Idiotype vaccine therapy) for follicular non-Hodgkin lymphoma in Europe and the US,
• Oncovex for melanoma
• Stimuvax (BLP25 liposome vaccine) for unresectable stage III NSCLC (non-small cell lung cancer).

Due to the launch of first-in-class vaccines during the forecast period the therapeutic cancer vaccines market is expected to show high growth.


High Unmet Need Exists in the Prophylactic and Therapeutic Cancer Vaccines Market

This research indicates there is high unmet need in the prophylactic and therapeutic cancer vaccines market in terms of there being more vaccines needed for different types of cancer.

In the prophylactic cancer vaccines market, there are only two vaccines available. The currently available prophylactic vaccines are for the prevention of cervical cancer. Therefore, there is high unmet need in the prophylactic cancer vaccines market in terms of the need for preventive vaccines for different types of cancer. In the prophylactic cancer vaccine pipeline there are only a small number of vaccines in the pipeline. Most of the vaccines are for the prevention of cervical cancer and for precancerous conditions. There are only two vaccines in the pipeline for other cancers: one is for cervical cancer and the other for breast cancer. To meet the unmet need, pharmaceutical companies need to research new preventive medicines.

There is high unmet need in the therapeutic cancer vaccines market. There is only one therapeutic cancer vaccine, Provenge, in the market. Provenge is only available in the US. Though there are many vaccines in the pipeline for different types of cancer, unmet need exists in terms of:

• Better understanding of most immunogenic antigens to be used for the treatment of different tumor types. Despite recent advances in therapy for cancer the median survival remains poor. Cancer vaccines might meet the unmet need for new and effective therapies with low toxicity. A better understanding of the immunology of cancer has led to novel strategies for vaccine delivery, including the use of immunogenic adjuvant agents, genetic modification of tumor cells to produce cytokines, viral vectors, and the use of antigen-presenting cells.
• Selection of the most potent adjuvant according to the route and schedule of administration. The adjuvant is selected to enhance the immune response of the vaccine, provide the long lasting effect of the vaccine and find out the correct route and schedule of administration of therapeutic vaccines, so there is an increase in the immunologic response to the vaccine.
• Identification of exact timing and number of vaccinations that should be given to cancer patients for them to have an enhanced immune response.
• Identification of non-immuno suppressive chemotherapeutic combination partners to be given with cancer vaccines to understand hich combinations should be given with the vaccine for there to be the maximum immune response.

To meet these unmet needs in the therapeutic cancer vaccines market, pharmaceutical companies must undergo rigorous research work to find solutions.

 
Major Companies Focusing on Therapeutic Cancer Vaccines Development Landscape

Vical, Biovest International, NewLink Genetics Corporation, NovaRx Corporation, Oxford BioMedica, immatics biotechnologies GmbH, GSK and Bavarian Nordic are going to be the key players in the future market. This study has profiled all of these companies as they hold important pipeline drugs in the late stages of development for cancer vaccines.

These companies are focusing on the development of therapeutic cancer vaccines for different types of cancer that will potentially change the future landscape of cancer vaccines.Apart from the companies mentioned above that are focusing in the development of therapeutic cancer vaccines, Dendreon is the first company to have introduced a therapeutic cancer vaccine to the market. The first therapeutic cancer vaccine, Provenge, for metastatic castrate resistant prostate cancer, is presently marketed in the US only. Dendreon is planning to file Provenge in Europe in early 2012 and it is expected to be launched in Europe in mid-2013. The launch of Provenge in Europe will drive the therapeutic cancer vaccine market and is going to change the landscape of the future therapeutic cancer vaccines market.


Strong Pipeline with First-in-Class Candidates Provides Hope for Cancer Treatment

The analysis shows that the cancer vaccines pipeline is strong, with first-in-class molecules in different stages of clinical development. There are currently 337 cancer vaccines in the different stages of clinical development. There are many first-in-class therapeutic cancer vaccines in Phase III clinical trials. These vaccines are a tumor vaccine, a dendritic cell vaccine, an antigen vaccine, a DNA vaccine, an anti-idiotype vaccine; a vector-based vaccine and a peptide vaccine, in terms of their mechanism of action.

These therapeutic vaccines, with better safety and tolerability profiles observed in clinical studies, have raised hope for cancer treatment in the future. Cancer vaccines are becoming increasingly promising, with possible combinations with chemotherapy, radiation and surgery. Consequently, cancer vaccines are believed to hold great promise as an adjuvant treatment.


About this new market study:
This report identifies the key trends shaping and driving the global Cancer Vaccines market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Cancer Vaccines sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.